Introgen cuts staff to focus on Advexin
This article was originally published in Scrip
Executive Summary
Introgen Therapeutics is to reduce its number of employees from 70 to 50 to focus on the development and commercialisation of its cancer therapy Advexin, a combination of a p53 tumour suppressor and a non-replicating, non-integrating adenoviral delivery system. Some of the remaining employees are expected to join Introgen's manufacturing subsidiary, Introgen Technical Services. Introgen recently achieved a milestone of filing for regulatory approval of Advexin in the US and Europe (Scrip No 3377, p 4).